logo-loader

Mindset Pharma selects two indications to target for its lead clinical candidate MSP-1014

Published: 14:35 13 Sep 2021 EDT

Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF, FRA:9DF) (CSE:MSET) (OTCQB:MSSTF) (FRA:9DF) CEO James Lanthier and Chief Scientific Officer Joseph Araujo joined Proactive to speak about how the group has selected Treatment-Resistant Depression (TRD) and End of Life Cancer Angst as initial target indications for its lead clinical candidate MSP-1014.

The company said MSP-1014 is a novel patent-pending drug candidate that, based on preclinical data, shows potential to be a safer second-generation psilocybin-like therapy with decreased potential for side effects.

Mindset Pharma discusses decision to expand into non-hallucinogenic drug...

Mindset Pharma CEO James Lanthier joins Natalie Stoberman from the Proactive studios to discuss the company's latest update to expand into non-hallucinogenic therapeutic drug discovery. Lanthier says Mindset has been one of the first biotech companies in the psychedelic space to apply state...

on 30/3/23